152 related articles for article (PubMed ID: 35694386)
1. Cell division cycle associated 2 (CDCA2) upregulation promotes the progression of hepatocellular carcinoma in a p53-dependant manner.
Wang J; Liu X; Chu H; Chen J
PeerJ; 2022; 10():e13535. PubMed ID: 35694386
[TBL] [Abstract][Full Text] [Related]
2. CDCA2 triggers in vivo and in vitro proliferation of hepatocellular carcinoma by activating the AKT/CCND1 signaling.
Li J; Chen Y; Wang X; Wang C
J BUON; 2021; 26(3):882-888. PubMed ID: 34268949
[TBL] [Abstract][Full Text] [Related]
3. CDCA2 promotes the proliferation of colorectal cancer cells by activating the AKT/CCND1 pathway in vitro and in vivo.
Feng Y; Qian W; Zhang Y; Peng W; Li J; Gu Q; Ji D; Zhang Z; Wang Q; Zhang D; Sun Y
BMC Cancer; 2019 Jun; 19(1):576. PubMed ID: 31196027
[TBL] [Abstract][Full Text] [Related]
4. CDCA2 Promotes HCC Cells Development via AKT-mTOR Pathway.
Li K; Fan T; Shi Z; Jiang H
Anal Cell Pathol (Amst); 2022; 2022():9912254. PubMed ID: 36588796
[TBL] [Abstract][Full Text] [Related]
5. Increased CDCA2 Level Was Related to Poor Prognosis in Hepatocellular Carcinoma and Associated With Up-Regulation of Immune Checkpoints.
Tang M; Liao M; Ai X; He G
Front Med (Lausanne); 2021; 8():773724. PubMed ID: 35372372
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of CDCA2 in human squamous cell carcinoma: correlation with prevention of G1 phase arrest and apoptosis.
Uchida F; Uzawa K; Kasamatsu A; Takatori H; Sakamoto Y; Ogawara K; Shiiba M; Bukawa H; Tanzawa H
PLoS One; 2013; 8(2):e56381. PubMed ID: 23418564
[TBL] [Abstract][Full Text] [Related]
7. CDCA2 promotes lung adenocarcinoma cell proliferation and predicts poor survival in lung adenocarcinoma patients.
Shi R; Zhang C; Wu Y; Wang X; Sun Q; Sun J; Xia W; Dong G; Wang A; Jiang F; Xu L
Oncotarget; 2017 Mar; 8(12):19768-19779. PubMed ID: 28423619
[TBL] [Abstract][Full Text] [Related]
8. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
Tian F; Cai D
Gene; 2022 Jan; 807():145964. PubMed ID: 34530087
[TBL] [Abstract][Full Text] [Related]
9. Identification of CDCA2 as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma.
Yu Z; Zhang Y; Shao S; Liu Q; Li Y; Du X; Zhang K; Zhang M; Yuan H; Yuan Q; Liu T; Gao Y; Wang Y; Hong W; Han T
Front Oncol; 2021; 11():755814. PubMed ID: 34660326
[TBL] [Abstract][Full Text] [Related]
10. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
11. CDCA2 protects against oxidative stress by promoting BRCA1-NRF2 signaling in hepatocellular carcinoma.
Wang S; Cao K; Liao Y; Zhang W; Zheng J; Li X; Huang M; Zhong Y; Hu X; Chen D; Wang Y
Oncogene; 2021 Jun; 40(25):4368-4383. PubMed ID: 34103686
[TBL] [Abstract][Full Text] [Related]
12. LAGE3 promoted cell proliferation, migration, and invasion and inhibited cell apoptosis of hepatocellular carcinoma by facilitating the JNK and ERK signaling pathway.
Xing Y; Liu Y; Qi Z; Liu Z; Wang X; Zhang H
Cell Mol Biol Lett; 2021 Nov; 26(1):49. PubMed ID: 34837962
[TBL] [Abstract][Full Text] [Related]
13. CDCA2 promotes tumorigenesis and induces radioresistance in oesophageal squamous cell carcinoma cells.
Xu B; Chen H; Xu Z; Yao X; Sun X; Cheng H
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34036376
[TBL] [Abstract][Full Text] [Related]
14. MiR-128-3p suppresses tumor proliferation and metastasis via targeting CDC6 in hepatocellular carcinoma cells.
Shi Y; Yan F; Wang F; Pan L
Tissue Cell; 2021 Oct; 72():101534. PubMed ID: 33991762
[TBL] [Abstract][Full Text] [Related]
15. CDCA2 promotes melanoma progression by inhibiting ubiquitin-mediated degradation of Aurora kinase A.
Sun W; Jin Y; Wei C; Xu Y; Liu W; Zhong J; Zou Z; Lin X; Xiang Y; Chen Y
Eur J Cancer; 2023 Jul; 188():49-63. PubMed ID: 37196484
[TBL] [Abstract][Full Text] [Related]
16. Cell division cycle associated 8: A novel diagnostic and prognostic biomarker for hepatocellular carcinoma.
Cui XH; Peng QJ; Li RZ; Lyu XJ; Zhu CF; Qin XH
J Cell Mol Med; 2021 Dec; 25(24):11097-11112. PubMed ID: 34741389
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of CENPM promotes hepatocarcinogenesis through mutiple mechanisms.
Xiao Y; Najeeb RM; Ma D; Yang K; Zhong Q; Liu Q
J Exp Clin Cancer Res; 2019 Nov; 38(1):458. PubMed ID: 31703591
[TBL] [Abstract][Full Text] [Related]
19. SKA3 Promotes tumor growth by regulating CDK2/P53 phosphorylation in hepatocellular carcinoma.
Hou Y; Wang Z; Huang S; Sun C; Zhao J; Shi J; Li Z; Wang Z; He X; Tam NL; Wu L
Cell Death Dis; 2019 Dec; 10(12):929. PubMed ID: 31804459
[TBL] [Abstract][Full Text] [Related]
20. Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53.
Calvisi DF; Simile MM; Ladu S; Frau M; Evert M; Tomasi ML; Demartis MI; Daino L; Seddaiu MA; Brozzetti S; Feo F; Pascale RM
Hepatology; 2011 Apr; 53(4):1226-36. PubMed ID: 21480327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
